Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery.

Srinivasan VM, Ghali MG, North RY, Boghani Z, Hansen D, Lam S.

Surg Neurol Int. 2016 Dec 28;7(Suppl 44):S1135-S1141. doi: 10.4103/2152-7806.196922. eCollection 2016. Review. No abstract available.

2.

Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data.

Mynarek M, Pizer B, Dufour C, van Vuurden D, Garami M, Massimino M, Fangusaro J, Davidson T, Gil-da-Costa MJ, Sterba J, Benesch M, Gerber N, Juhnke BO, Kwiecien R, Pietsch T, Kool M, Clifford S, Ellison DW, Giangaspero F, Wesseling P, Gilles F, Gottardo N, Finlay JL, Rutkowski S, von Hoff K.

Neuro Oncol. 2017 Apr 1;19(4):576-585. doi: 10.1093/neuonc/now234.

PMID:
28011926
3.

Adjuvant chemotherapy and overall survival in adult medulloblastoma.

Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB.

Neuro Oncol. 2017 Feb 1;19(2):259-269. doi: 10.1093/neuonc/now150.

PMID:
27540083
4.

Molecular subgroups of adult medulloblastoma: a long-term single-institution study.

Zhao F, Ohgaki H, Xu L, Giangaspero F, Li C, Li P, Yang Z, Wang B, Wang X, Wang Z, Ai L, Zhang J, Luo L, Liu P.

Neuro Oncol. 2016 Jul;18(7):982-90. doi: 10.1093/neuonc/now050. Epub 2016 Apr 21.

5.

Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival.

Eaton BR, Esiashvili N, Kim S, Weyman EA, Thornton LT, Mazewski C, MacDonald T, Ebb D, MacDonald SM, Tarbell NJ, Yock TI.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):133-8. doi: 10.1016/j.ijrobp.2015.09.014. Epub 2015 Sep 18.

6.

Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis.

Cox MC, Kusters JM, Gidding CE, Schieving JH, van Lindert EJ, Kaanders JH, Janssens GO.

Radiat Oncol. 2015 Nov 24;10:241. doi: 10.1186/s13014-015-0547-9.

7.

Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells.

Silva PB, Rodini CO, Kaid C, Nakahata AM, Pereira MC, Matushita H, Costa SS, Okamoto OK.

Cytotechnology. 2016 Aug;68(4):1545-60. doi: 10.1007/s10616-015-9914-5. Epub 2015 Sep 10.

PMID:
26358937
8.

Medulloblastoma.

Millard NE, De Braganca KC.

J Child Neurol. 2016 Oct;31(12):1341-53. doi: 10.1177/0883073815600866. Epub 2015 Sep 2. Erratum in: J Child Neurol. 2016 Sep 15;:.

PMID:
26336203
9.

Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.

Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG.

J Clin Oncol. 2015 Sep 20;33(27):2986-98. doi: 10.1200/JCO.2014.59.9217. Epub 2015 Aug 24. Review.

10.

A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.

Wang F, Remke M, Bhat K, Wong ET, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke ST, Wu L, Li DW, Hawkins C, Kohane IS, Wu JM, Wu M, Taylor MD, Wu E.

Oncotarget. 2015 Feb 20;6(5):2709-24.

11.

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance.

Lindsey JC, Kawauchi D, Schwalbe EC, Solecki DJ, Selby MP, McKinnon PJ, Olson JM, Hayden JT, Grundy RG, Ellison DW, Williamson D, Bailey S, Roussel MF, Clifford SC.

Oncogene. 2015 Sep 3;34(36):4746-57. doi: 10.1038/onc.2014.405. Epub 2014 Dec 22.

13.

Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells.

Fan YN, Meley D, Pizer B, Sée V.

PLoS One. 2014 Sep 24;9(9):e108514. doi: 10.1371/journal.pone.0108514. eCollection 2014.

14.

Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors.

Odagiri K, Omura M, Hata M, Aida N, Niwa T, Goto H, Ito S, Adachi M, Yoshida H, Yuki H, Inoue T.

Radiat Oncol. 2014 Sep 11;9:201. doi: 10.1186/1748-717X-9-201.

15.

Overcoming multiple drug resistance mechanisms in medulloblastoma.

Othman RT, Kimishi I, Bradshaw TD, Storer LC, Korshunov A, Pfister SM, Grundy RG, Kerr ID, Coyle B.

Acta Neuropathol Commun. 2014 May 30;2:57. doi: 10.1186/2051-5960-2-57.

16.

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors.

Bull KS, Kennedy CR, Bailey S, Ellison DW, Clifford SC.

Acta Neuropathol. 2014 Jul;128(1):151-3. doi: 10.1007/s00401-014-1300-4. Epub 2014 May 31. No abstract available.

17.

Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma.

Akino T, Han X, Nakayama H, McNeish B, Zurakowski D, Mammoto A, Klagsbrun M, Smith E.

Cancer Res. 2014 Jul 15;74(14):3716-26. doi: 10.1158/0008-5472.CAN-13-3116. Epub 2014 May 8.

18.

Comparison of survival between the UK and US after surgery for most common pediatric CNS tumors.

Mathew RK, O'Kane R, Parslow R, Stiller C, Kenny T, Picton S, Chumas PD.

Neuro Oncol. 2014 Aug;16(8):1137-45. doi: 10.1093/neuonc/nou056. Epub 2014 May 5.

19.

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

Cefalo G, Massimino M, Ruggiero A, Barone G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garrè ML, Perilongo G, Madon E, Colosimo C, Riccardi R.

Neuro Oncol. 2014 May;16(5):748-53. doi: 10.1093/neuonc/not320. Epub 2014 Jan 30.

20.

Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature.

Kotecha RS, Buckland A, Phillips MB, Cole CH, Gottardo NG.

J Pediatr Hematol Oncol. 2014 Jan;36(1):76-80. doi: 10.1097/MPH.0b013e3182a8f352. Review.

Supplemental Content

Support Center